Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06432075
Other study ID # Neoantigen T Cells
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date June 1, 2024
Est. completion date December 1, 2026

Study information

Verified date May 2024
Source First Affiliated Hospital of Wenzhou Medical University
Contact Xian Shen
Phone 13968888872
Email 13968888872@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) in the treatment of Chinese patients with advanced gastric cancer.


Description:

The tumor-specific "none-self" immunogenic neoantigens encoded by either viral genes or somatic mutation genes, possess the potential to induce specific anti-cancer immunity, including cellular and humoral immune responses. Today, numerous clinical trials demonstrate that although these "none-self" antigens initiate the antigen-specific immunoglobulin G antibodies and cluster of differentiation 4(CD4)+/cluster of differentiation 8(CD8)+T-cells response, not all of them show a clinical benefit in the response rate, progression-free survival or overall survival.Personalized cell therapy maybe own a breakthrough in the treatment of those gastric cancer patients without standard options.The investigators' center has successfully established a new method for preparing personalized neoantigen reactive T cells(NRTS) for adoptive cell therapy(ACT). Today, the investigators will carry out a single arm clinical prospective study of NRTs for the treatment of Chinese patients with advanced gastric cancer. Participants are assigned to receive 4 circles of cell therapy, and IL-2 continuous intravenous infusion(CIV) will also be given for 5 consecutive days after each time's cell infusion. The safety and clinical response rate(RR) are evaluated. Biomarkers and immunological markers are also monitored.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date December 1, 2026
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Voluntarily join the study and sign the informed consent; 2. Age: 18-75 years old, male or female; 3. Subjects with advanced gastric cancer who had received systematic standard treatment before enrollment and had no effective treatment at present. (Note: The effective treatment means refer to the latest version of the "Gastric Cancer Diagnosis and Treatment Guide" issued by China's "Chinese Clinical Oncology Society".) ; 4. Have at least one measurable lesion according to imRECIST evaluation criteria; 5. Expected survival =5 months (starting from the collection of tissue samples for sequencing); 6. The Eastern Cancer Consortium (ECOG) score was 0 or 1 or 2; 7. The following hematological indicators should be met: neutrophil count = 1.5×109/L; Hemoglobin = 10.0 g/dL; Platelet count = 50×109/L; 8. The following biochemical indicators should be met: total bilirubin =2.0× upper limit of normal value (ULN); AST and ALT =2.0×ULN; Serum creatinine =1.5×ULN. 9. Before lymphocyte clearance preadministration: 1) any chemotherapy, small molecule targeted drugs and other antitumor therapy received have passed the 3-week washout period, and the toxic side effects have returned to grade 1 or lower (excluding hair loss, vitiligo and other events as determined by the investigator to be tolerated); 2) If surgical treatment is performed within 3 weeks, toxicity has returned to grade 1 or lower; 3) The immunotoxicity of major organs has returned to grade 1 or lower after receiving any antibody drug treatment, and the washout period of PD-1 antibodies has reached 6 weeks, and CTLA-4 antibodies and other antibodies have passed the washout period of 4 weeks. Exclusion Criteria: 1. Subjects infected with HBV, HCV, HIV, syphilis and tuberculosis; 2. Uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease or what the investigator considers Other diseases not included in the group; 3. Patients with a history of bone marrow or organ transplantation; Patients with coagulation dysfunction; 4. Patients with immune deficiency diseases or autoimmune diseases who are treated with immunosuppressive drugs; 5. Central nervous system (CNS) metastatic and/or cancerous meningitis; 6. People who may be allergic to immunotherapy; 7. Drug abuse, clinical or psychological or social factors that affect informed consent or the conduct of the study; 8. Pregnant and lactating women; 9. Participating in other clinical trials; 10. An uncertainty that the investigator believes has an impact on the subject's safety or compliance.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Neoantigen Reactive T Cells(NRTs)
Neoantigen Reactive T Cells in an expected volume of 100 milliliter(mL) will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital of Wenzhou Medical University

Outcome

Type Measure Description Time frame Safety issue
Other Overall Survival (OS) the duration is measured from the time of treatment to the time of death Visits were conducted at the end (or termination) of each course and at 30, 90, and 120 days after the end of the last course for 4 months
Other Interferon-gama change of PBMC cells in the peripheral blood stimulated by tumor antigens T cells in the peripheral blood stimulated by tumor antigens for 24 hr,and then Interferon-gama secretion is measured Visits were conducted at the end (or termination) of each course and at 30, 90, and 120 days after the end of the last course for 4 months
Primary Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients up to 6 months
Secondary Response Rate Response Rate(RR)will be evaluated according Response Evaluation Criteria in Solid Tumors Visits were conducted at the end (or termination) of each course and at 30, 90, and 120 days after the end of the last course for 4 months
Secondary Progression free survival (PFS) the duration of progression free survival is measured from the time of treatment to the first date that recurrent or progressive disease or for any reason of death is objectively documented. Visits were conducted at the end (or termination) of each course and at 30, 90, and 120 days after the end of the last course for 4 months
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Completed NCT00821990 - Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer Phase 3
Recruiting NCT04385641 - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer N/A
Completed NCT01248403 - A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy Phase 3
Not yet recruiting NCT01206218 - Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer Phase 2/Phase 3
Completed NCT01851941 - A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer Phase 2
Completed NCT00976768 - Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin Phase 2
Active, not recruiting NCT03223376 - A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) Phase 3
Completed NCT03609359 - Lenvatinib and Pembrolizumab Simultaneous Combination Study Phase 2
Completed NCT03350477 - Bioinformation Therapy for Gastric Cancer Phase 2/Phase 3
Completed NCT02935634 - A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Phase 2
Active, not recruiting NCT03579784 - Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer Phase 2
Completed NCT02952729 - Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Phase 1
Recruiting NCT02072317 - Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Phase 2
Completed NCT01472250 - A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China N/A
Terminated NCT01402401 - Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients Phase 2
Completed NCT01503372 - FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer Phase 2
Recruiting NCT01015339 - Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 3
Completed NCT01441336 - Laparoscopic Gastrectomy for Advanced Gastric Cancer Phase 2
Completed NCT02071043 - Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis Phase 2